Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the safety and effectiveness of BMS-986165 compared with placebo with regard to measures of kidney function in participants with lupus nephritis (LN).
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Bristol-Myers Squibb
NCT06434363 · Autoimmune Disorders, Systemic Sclerosis, and more
NCT05126277 · Lupus Nephritis
NCT05538208 · Lupus Nephritis
NCT07015983 · Lupus Erythematosus, Systemic, Lupus Nephritis
NCT06947460 · Refractory Lupus Nephritis, Systemic Sclerosis, and more
University of Alabama at Birmingham
Birmingham, Alabama
The Nephrology Group
Fresno, California
The Regents of The University of California
Los Angeles, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions